Assess the effectiveness of the Australian Pancreatic High-RIsk ScrEening Program in identifying early-stage pancreatic cancer among high-risk individuals due to familial or genetic risk factors

Epworth HealthCare0 sites500 target enrollmentStarted: April 8, 2024Last updated: April 15, 2024

Conditions

Trial Snapshot

No summary available.

•Individuals aged 18 to 90 years old (inclusive) without history of PDAC meeting any of the following criteria:
•a)2 or more relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject and age 50+ years or 10 years younger than earliest PDAC in family at time of diagnosis.
•b)2 or more affected first degree relatives with PDAC and age 50+ or 10 years younger than earliest PDAC in family.
•c)BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant and 1 first or second degree relative with PDAC and age 50+ or 10 years younger than earliest PDAC in family.
•d)Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant and age 40+.
•e)Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant and age 35+.
•f)Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis and age 40+ or 20 years after onset of pancreatitis (whichever is earlier).

•Participants will be excluded if they are considered clinically unfit to undergo surveillance by EUS or MRI.

Sponsor

Epworth HealthCare